학술논문
An open‐label, multi‐centre, post‐marketing study to assess the efficacy and safety of a plasma‐derived VWF/FVIII concentrate in patients with von Willebrand disease.
Document Type
Article
Author
Source
Subject
*VON Willebrand disease
*INFORMED consent (Medical law)
*SURGICAL blood loss
*
*
Language
ISSN
1351-8216
Abstract
This article presents the findings of a post-marketing study on the use of a plasma-derived von Willebrand Factor (VWF)/factor VIII (FVIII) concentrate for the treatment of von Willebrand disease (VWD). VWD is a common inherited bleeding disorder. The study included patients of all ages with severe types of VWD. The results showed that the treatment was well-tolerated and provided effective control of bleeding for both adult and pediatric patients. The study supports the use of this treatment for VWD. [Extracted from the article]